


## PHARMACEUTICAL 2023

## Moleculin Biotech Inc. Rank 104 of 446









## PHARMACEUTICAL 2023



## Moleculin Biotech Inc. Rank 104 of 446



The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Moleculin Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 150% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,596
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,819
Liabilities, Non-Current	335
Other Assets	11,551
Other Compr. Net Income	-29
Other Expenses	-1,075
Other Liabilities	77
Other Net Income	280
Other Revenues	0
Property and Equipment	275
Research and Development	18,968
Selling, General and Administrative Expense	11,542

Output Variable	Value in 1000 USD
Assets	57,422
Liabilities	5,231
Expenses	29,435
Revenues	0
Stockholders Equity	52,191
Net Income	-29,155
Comprehensive Net Income	-29,170
Economic Capital Ratio	193%

